Literature DB >> 9014602

Relationship between disease severity and inflammatory markers in cystic fibrosis.

D Y Koller1, M Götz, C Wojnarowski, I Eichler.   

Abstract

To evaluate the clinical use of measuring neutrophil, lymphocyte, and eosinophil activities, serum myeloperoxidase (MPO), soluble interleukin-2 receptors (sIL-2R), and eosinophil cationic protein (ECP) were measured in 98 patients with cystic fibrosis and in 85 healthy children. Serum concentrations of MPO, sIL-2R, and ECP were increased in patients with cystic fibrosis (median 807 micrograms/l, 4452 pg/ml, 48.8 micrograms/l, respectively) compared with the controls (median 319 micrograms/l, 2743 pg/ml, 9.4 micrograms/l). ECP concentrations, but not serum MPO or sIL-2R, were significantly related to disease severity assessed by the Shwachman-Kulczycki score and by pulmonary function (forced expiratory volume in one second % predicted). Neither ECP nor sIL-2R was influenced by Pseudomonas aeruginosa infection, acute pulmonary exacerbation, or atopy. Serum MPO, however, was strongly correlated with acute pulmonary exacerbation. In the light of these findings the measurement of serum ECP might thus be used for clinical monitoring and for assessing disease severity in cystic fibrosis. The measurement of serum MPO and sIL-2R did not correlate with the disease severity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014602      PMCID: PMC1511810          DOI: 10.1136/adc.75.6.498

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  12 in total

1.  Raised serum soluble interleukin-2 receptor concentrations in cystic fibrosis patients with and without evidence of lung disease.

Authors:  E Dagli; J A Warner; C R Besley; J O Warner
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

2.  Clinical relevance of raised soluble serum interleukin-2 receptor concentrations in cystic fibrosis.

Authors:  D Y Koller; M Götz
Journal:  Arch Dis Child       Date:  1993-01       Impact factor: 3.791

3.  Purification and cytotoxic potential of myeloperoxidase in cystic fibrosis sputum.

Authors:  J R Mohammed; B S Mohammed; L J Pawluk; D M Bucci; N R Baker; W B Davis
Journal:  J Lab Clin Med       Date:  1988-12

4.  A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group.

Authors:  H Eigen; B J Rosenstein; S FitzSimmons; D V Schidlow
Journal:  J Pediatr       Date:  1995-04       Impact factor: 4.406

5.  Serum myeloperoxidase and lactoferrin in neutropenia.

Authors:  T Olofsson; I Olsson; P Venge; B Elgefors
Journal:  Scand J Haematol       Date:  1977-01

6.  Effect of high-dose ibuprofen in patients with cystic fibrosis.

Authors:  M W Konstan; P J Byard; C L Hoppel; P B Davis
Journal:  N Engl J Med       Date:  1995-03-30       Impact factor: 91.245

7.  Mucociliary clearance in patients with cystic fibrosis and in normal subjects.

Authors:  J A Regnis; M Robinson; D L Bailey; P Cook; P Hooper; H K Chan; I Gonda; G Bautovich; P T Bye
Journal:  Am J Respir Crit Care Med       Date:  1994-07       Impact factor: 21.405

8.  Eosinophilic activation in cystic fibrosis.

Authors:  D Y Koller; M Götz; I Eichler; R Urbanek
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

9.  Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle. Role of the epithelium.

Authors:  N A Flavahan; N R Slifman; G J Gleich; P M Vanhoutte
Journal:  Am Rev Respir Dis       Date:  1988-09

10.  Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo.

Authors:  C G Peterson; I Enander; J Nystrand; A S Anderson; L Nilsson; P Venge
Journal:  Clin Exp Allergy       Date:  1991-09       Impact factor: 5.018

View more
  7 in total

1.  Environmental allergies and respiratory morbidities in cystic fibrosis.

Authors:  Joseph M Collaco; Christopher B Morrow; Deanna M Green; Garry R Cutting; Peter J Mogayzel
Journal:  Pediatr Pulmonol       Date:  2012-11-09

2.  Intestinal inflammation in cystic fibrosis.

Authors:  R L Smyth; N M Croft; U O'Hea; T G Marshall; A Ferguson
Journal:  Arch Dis Child       Date:  2000-05       Impact factor: 3.791

Review 3.  Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.

Authors:  Sabina Schmitt-Grohé; Stefan Zielen
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Expression of S100A12 (EN-RAGE) in cystic fibrosis.

Authors:  D Foell; S Seeliger; T Vogl; H-G Koch; H Maschek; E Harms; C Sorg; J Roth
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

5.  Potential of anti-inflammatory treatment for cystic fibrosis lung disease.

Authors:  Jennifer L Taylor-Cousar; Kelsey A Von Kessel; Robert Young; David P Nichols
Journal:  J Inflamm Res       Date:  2010-08-10

6.  Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice.

Authors:  Rachida Legssyer; François Huaux; Jean Lebacq; Monique Delos; Etienne Marbaix; Patrick Lebecque; Dominique Lison; Bob J Scholte; Pierre Wallemacq; Teresinha Leal
Journal:  Respir Res       Date:  2006-10-25

Review 7.  Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis.

Authors:  Adam J Causer; Janis K Shute; Michael H Cummings; Anthony I Shepherd; Mathieu Gruet; Joseph T Costello; Stephen Bailey; Martin Lindley; Clare Pearson; Gary Connett; Mark I Allenby; Mary P Carroll; Thomas Daniels; Zoe L Saynor
Journal:  Redox Biol       Date:  2020-01-23       Impact factor: 11.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.